Regencell Bioscience (NASDAQ:RGC) Stock Price Down 5.1% – What’s Next?

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) traded down 5.1% during trading on Tuesday . The company traded as low as $24.30 and last traded at $24.48. 100,662 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 305,052 shares. The stock had previously closed at $25.80.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm’s 50 day simple moving average is $27.71 and its 200 day simple moving average is $24.81.

Regencell Bioscience (NASDAQ:RGC) last posted its quarterly earnings results on Friday, May 8th. The company reported $0.00 EPS for the quarter.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP purchased a new position in shares of Regencell Bioscience during the fourth quarter worth approximately $92,000. Amundi purchased a new position in shares of Regencell Bioscience during the first quarter worth approximately $219,000. Hudson Bay Capital Management LP purchased a new position in shares of Regencell Bioscience during the fourth quarter worth approximately $275,000. Bank of America Corp DE raised its stake in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after acquiring an additional 17,143 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Regencell Bioscience during the third quarter worth approximately $598,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.